Management of hair loss
||It has been suggested that this article be merged into Management of androgenic alopecia. (Discuss) Proposed since September 2013.|
|Management of baldness|
|Classification and external resources|
Hair loss has been a field of study since ancient times
The management of baldness is a multidisciplinary effort that spans the medical, pharmaceutical, food supplement, exercise and fashion industries. Androgenic alopecia, alopecia areata, and telogen effluvium are the primary nonscarring alopecias. The most common cause of hair loss in men is androgenic alopecia, the early stages of which can be slowed or reversed with medication, while more advanced cases may be amenable to hair transplantation. Alopecia areata presents as focal discoid patches of hair loss, and affects up to 2% of the U.S. population, occurring more often in children. Telogen effluvium can occur after stressful events, including severe illness, childbirth, or high fever, and can be seen with certain medications or deficiency of iron, particularly in females. Thyroid dysfunction, both when increased and decreased, can lead to specific patterns of hair loss.
- 1 Androgenic alopecia
- 1.1 Androgenic impact of exercise
- 1.2 Conventional medication
- 1.3 Hair transplantation
- 1.4 Experimental medication
- 1.5 Laser therapy
- 1.6 Dietary supplements
- 1.7 Stem cell therapy
- 1.8 Genetics
- 2 Radiation induced alopecia
- 3 Cosmeses
- 4 See also
- 5 References
- 6 External links
Androgenic hair loss is due to the activity of androgens, predominantly DHT, at the dermal papillae of the individual follicles. In adult men, its incidence is roughly equivalent to chronologic age, and it has a strong genetic component.
The physiology is primarily androgenic, with dihydrotestosterone (DHT) the major contributor. Androgens are important in male sexual development around birth and at puberty. They regulate sebaceous glands, apocrine hair growth and libido. With increasing age, androgens stimulate hair growth on the face, but suppress it at the temples and scalp vertex, a condition that has been referred to as the 'androgen paradox'.
Several lines of evidence support the dermal papilla of the hair follicle as the androgenic target for hair loss prevention and reversal. Type 1 and 2 5α reductase enzymes are present at pilosebaceous units in papillae of individual hair follicles. They catalyze formation of the androgens testosterone and DHT, which in turn regulate hair growth. Androgens have different effects at different follicles: they stimulate IGF-1 at facial hair, causing hair regrowth, but stimulate TGF β1, TGF β2, dickkopf1 and IL-6 at the scalp, causing hair follicle miniaturization.
Female androgenic alopecia is characterized by diffuse crown thinning without hairline recession, and like its male counterpart rarely leads to total hair loss. Finasteride and minoxidil are usually first line therapy for its treatment. Other options include topical or systemic spironolactone or flutamide, although they have a high incidence of feminizing side effects and are better tolerated in female androgenic hair loss.
More advanced cases may be resistant or unresponsive to medical therapy, however, and require hair transplantation. Naturally-occurring units of one to four hairs, called follicular units, are excised and moved to areas of hair restoration. These follicular units are surgically implanted in the scalp in close proximity and in large numbers. The grafts are obtained from either Follicular Unit Transplantation (FUT), colloquially referred to as 'strip harvesting,' or Follicular Unit Extraction (FUE). In the former, a strip of skin with follicular units is extracted and dissected into individual follicular unit grafts. The surgeon then implants the grafts into small incisions, called recipient sites. Specialized scalp tattoos can also mimic the appearance of a short buzzed haircut. Androgenic alopecia also occurs in females, and more often presents as diffuse thinning without hairline recession. Like its male counterpart, the condition rarely leads to total hair loss. Treatment options are similar to those for men, although topical or systemic estrogen is used more often.
Androgenic impact of exercise
Exercise can impact androgenic hair loss at least partially by affecting androgen and estrogen levels.
Quantification of androgen indices in response to exercise can be understood in four categories: short versus long term, and anaerobic versus aerobic. These are indirect assays of exercise impact on hair loss, although the ability of exogenous androgen to worsen or precipitate miniaturization in the genetically predisposed is well documented. Investigations have been either self-report, or cross-sectional and cohort studies with exercise and serum hormonal indices, but no phase III clinical trials. In some studies, conflicting results are thought related to differences in exercise mode, volume, or physical condition of subjects.
In cross-sectional analyses, aerobic exercisers have lower basal total and free testosterone compared to the sedentary. Anaerobic exercisers also have lower testosterone compared to the sedentary but a slight increase in basal testosterone with resistance training over time. Acutely, testosterone briefly increases when comparing aerobic, anaerobic and mixed forms of exercise. A study assessed men who were resistance trained, endurance trained, or sedentary in which they either rested, ran or did a resistance session. Androgens increased in response to exercise, particularly resistance, while cortisol only increased with resistance. After initial post-exercise increase, there was decline in free and total testosterone during resistance recovery, particularly in resistance-trained subjects. Endurance-trained subjects showed less change in hormone levels in response to exercise than resistance-trained subjects. Another study found relative short term effects of aerobic, anaerobic and combined anaerobic-aerobic exercise protocols on hormone levels to not be different. It showed increases in testosterone and cortisol immediately after exercise that returned to baseline in 2 hours.
In trained long term aerobic exercisers, basal androgen levels are unchanged, or decreased. Acutely, endurance based aerobic efforts cause testosterone to rise. A year long, moderate-intensity aerobic exercise program increased DHT and SHBG in sedentary men age 40-75, but had no effect on other androgens. Both DHT and SHBG increased 14% in exercisers at 3 months, and at 12 months they remained 9% above baseline. SHBG is protective against DHT as it binds free androgen.
It is unknown if anaerobic training changes individual hormone profiles, or if conditioned athletes in studies self-selected because of physiologic predisposition to athletic conditioning. There is variation of response to anaerobic stress depending on exercise intensity, age, gender, length of time studied, and time at which serum indices were drawn. Most studies report that testosterone increases or is unchanged acutely, though some even report it to decrease. Anaerobic exercisers have testosterone levels below sedentary controls in cross sectional analysis. Over months to years, levels are stable to slightly increased.
The ratio of testosterone to cortisol can both increase and decrease during resistance training, depending on intensity of exercise. When comparing men and women in the 30, 50 and 70 year age groups, young and middle aged men showed increased testosterone after exercise, with the latter also having increased cortisol. Elderly men showed no change. There is a 27% greater testosterone response using protocols with simultaneous use of all four limbs. A number of studies have looked at effects of anaerobic exercise over months to years, showing it to be constant or slightly increased. A small case-control of anaerobic training in young untrained males over six weeks found decline in free testosterone of 17 percent. With men in their 60s, resistive training over 16 weeks did not affect baseline anabolic hormone levels, although GH increased acutely with exercise. A study over 21 weeks in male strength athletes showed basal hormone levels to be constant, despite strength increase. A follow up study looked at a larger group of weight trainers over 24 weeks, with 12 week decompensation. Training caused no change in total testosterone, but there were decreases in free testosterone, progesterone, androstendione, DHEA, cortisol, transcortin, and in the cortisol:CBG ratio, suggesting androgen turnover increased with training intensity, without change in total testosterone. A study looking at young men and resistance training over 48 weeks found increases in baseline serum testosterone from 20 ± 5 to 25 ± 5 nmol/l, and an increase in testosterone:SHBG ratio, LH and FSH.
One study showed GH increase with anaerobic effort to be blunted in those who performed aerobic training for 60 minutes prior to strength training. Testosterone levels remained high only at the end of the training session with aerobic training followed by strength training, a phenomenon not seen with weight training done before aerobics. In an 11 week soccer training program focusing on combined vertical jumps, short sprints, and submaximal endurance running, total testosterone increased, but SHBG rose in parallel, maintaining a constant free androgen index.
The two first line medications in treatment of male pattern baldness are minoxidil (Rogaine) and finasteride (Propecia). Both are recommended as first-line treatment for male pattern baldness. They may also be used simultaneously when hair loss is progressive or further regrowth is desired after 12 months. A number of other medications used commonly off-label are dutasteride and ketoconazole, and in female androgenic alopecia spironolactone and flutamide. Combinations of finasteride, minoxidil and ketoconazole are more effective than individual use, suggesting synergistic effects of the medications.
5 alpha reductase inhibitors
Finasteride (marketed by Merck under the trade names Propecia and Proscar) is a type-2 isoenzyme 5 alpha-reductase inhibitor. It was originally FDA approved for treatment of benign prostatic hyperplasia (BPH). Finasteride binds to 5-alpha-reductase, preventing conversion of testosterone to DHT. Its effects on androgenic alopecia were not unexpected due to observations of the pseudo-hemaphrodite population in Papua, New Guinea. Both systemic and topical formulations are effective in androgenic hair loss.
Inhibition of 5α-reductase results in decreased conversion of testosterone to dihydrotestosterone (DHT) by reducing the Δ4,5 double-bond. This, also leads to increased levels of testosterone and estradiol. Gynecomastia, erectile dysfunction and depression, are some possible side-effects. Other locally expressed enzymes can compensate to a degree, including DHT conversion through reductive 17b-hydroxysteroid dehydrogenase, oxidative 3a-hydroxysteroid dehydrogenase, and 3b-hydroxysteroid dehydrogenase enzymes.
In clinical studies, finasteride, like minoxidil, is effective at the crown and frontal hairline area, but more so at the former. A study over 2 years with 1,553 men between ages 18 and 41 with mild to moderate hair thinning taking 1 mg/day showed 83% maintained or increased hair growth. In 1997, the drug was FDA approved for male pattern baldness. A 5-year study revealed that 9 of 10 men taking finasteride at 1 mg/day experienced results. 42% had no further loss while 48% experienced regrowth.
The drug is lipophilic, and development of a liposomal system of finasteride for topical application has been a subject of recent study, with vehicles shown stable for up to two months in refrigerated preparation. Topical formulations show some effect in reversal of androgenic effects on hair follicles, as well as in hirsutism. Studies of transgenic mice have shown hair regrowth with topical administration. More recent studies have looked at microemulsions and liquid crystalline nanoparticles for topical finasteride delivery. In the latter, addition of glycerol, propylene glycol, and polyethylene glycol 400, increased finasteride permeation, while addition of oleic acid made it decrease. Topical 0.1% finasteride in combination with topical 3% minoxidil is more effective than topical minoxidil alone. Small studies of topical finasteride formulations in combination with other drugs have also been found effective. Surfactants have been shown to aid topical absorption. Topical finasteride gel has been shown an effective route of administration. Of note, the studies evaluating topical finasteride did not correlate with serum PSA in humans, or prostatic weight in animal studies to see if effects were related to systemic absorption. Other studies have shown lower doses of topical finasteride to be less effective. The medication is not entirely benign. Some patients experience neurologic or psychiatric sequellae after discontinuation of the drug, a condition described in medical literature as 'post-finasteride syndrome'.
Dutasteride (trademark name Avodart, manufactured by GlaxoSmithKline) is approved for the treatment of benign prostatic hyperplasia (BPH), and used off label for androgenic alopecia. It is a dual 5-a reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone (DHT). The drug inhibits all 2 isoforms of 5-alpha reductase, whereas finasteride only inhibits type II.
Phase I and II clinical trials for dutasteride as a hair loss drug were started, but discontinued in late 2002 for unknown reasons. Phase II studies showed that dutasteride, at both 0.5 mg and 2.5 mg per day, showed a superior hair count as compared to finasteride 5 mg at 3 and 6 months.
Phase II results at 24 weeks showed placebo to decrease by 32 hairs, dutasteride 0.5 mg to increase an average of 95 hairs, while the dutasteride 2.5 mg group increasing by 110 hairs. GlaxoSmithKline ran a phase III, six month study in Korea to test the safety, tolerability and effectiveness of a once-daily dutasteride at 0.5 mg. They looked at male pattern baldness (MPB) at the vertex of the scalp, types III, IV and V on the Hamilton-Norwood scale. The study completed in January 2009. Future intentions by GlaxoSmithKline for FDA approval of dutasteride in androgenic alopecia are unknown.
Other topical treatments
Minoxidil and ketoconazole are two long standing topical treatments of androgenic alopecia, with only the former having FDA approval for androgenic alopecia in the United States. Ketoconazole is also used as an anti-fungal in the treatment of tinea capitis. Ketoconazole is an ingredient in hair shampoos like Nizoral and Regenepure. 
Minoxidil (Rogaine) is a vasodilator. It was originally used as the oral drug Loniten to treat hypertension, and discovered to cause hair growth as a side effect. Upjohn received FDA approval to market a topical solution that contained 2% minoxidil as Rogaine, marketed outside the United States as Regaine.
It is effective at both the front and scalp vertex. In a 12 month study, vertex improvements were seen in 51% of men using 5% minoxidil, 42% using 2% minoxidil, and 13% of placebo users. Moderate to great increases in hair growth were seen in the frontal scalp regions of 19% of men using 5% minoxidil, 10% using 2% minoxidil, and 3% of placebo. Although a mitogen for dormant telogen follicles, minoxidil can cause hairs in later phases of the cell cycle to shed early. This is often followed by growth of new, thicker hairs. The mitogenic effect is temporary and does not appear to change follicular structure, leading to indefinite minoxidil application to maintain growth. The use of minoxidil without propylene glycol as a minoxidil delivery vehicle can reduce itching caused by the propylen glycol. Minoxidil can also be combined with other active ingredients such as tretinoin.
Please note that the increasing amount of research and development in the field has caused a surge in the number of products claiming to tackle the hair loss. Rogaine, Kirkland minoxidil, Lipogaine are some of the popular hair loss products that contain minoxidil.
Ketoconazole is a mild topical anti-androgen available over the counter and in prescription strength in the United States. It is established as treatment for tinea capitis, but also has anti-androgenic and microfloral benefit in androgenic hair loss. Spironolactone and flutamide are potent topical and systemic anti-androgens, typically not used in men as they have a high incidence of feminizing side effects. They can be prescribed off-label as part of a more aggressive medical regimens, and are effective in female androgenic hair loss.
Ketoconazole is a topical anti-fungal agent. As an imidazole, ketoconazole is effective for the treatment of dermatitis and dandruff, and its action on scalp microflora may benefit those with AGA associated follicular inflammation. It is also an anti-androgen, and may improve hair growth in AGA through androgen dependent pathways.
Spironolactone is a possible selective androgen receptor modulator, and both reduces adrenal androgen production and exerts competitive blockade on androgen receptors in target tissues. It can be administered topically or systemically. In addition to anti-androgenic activity, it increases estrogen production, which in turn increases production of SHBG. SHBG binds free DHT and decreases free androgen indices. Due to its feminizing side effects and risk of infertility in men It is used more often in female androgenic alopecia, particularly PCOS. As it is also an anti-hypertensive, patients need to be monitored for hyperkalemia and associated cardiac dysrhythmia. Also, women who are pregnant or trying to become pregnant generally cannot use the medication as it is a teratogen, and can cause ambiguous genitalia in newborns.
Flutamide has more anti-androgenic activity than spironolactone, and is also referred to as chemical castration. It can cause marked reduction in libido and estrogenic side effects including gynecomastia, lipid profile changes, and emotional lability, although when used in women it can be associated with increased positive affect. There is a significant incidence of hepatic dysfunction with the medication in women. Like spironolactone, it is more often used clinically in female androgenic alopecia.
Hair transplantation is a surgical technique that moves individual hair follicles from a part of the body called the 'donor site' to bald or balding part of the body known as the 'recipient site'. It is primarily used to treat male pattern baldness. In this condition, grafts containing hair follicles that are genetically resistant to balding are transplanted to bald scalp. It is also used to restore eyelashes, eyebrows, beard hair, chest hair, and pubic hair and to fill in scars caused by accidents or surgery such as face-lifts and previous hair transplants. Hair transplantation differs from skin grafting in that grafts contain almost all of the epidermis and dermis surrounding the hair follicle, and many tiny grafts are transplanted rather than a single strip of skin.
Since hair naturally grows in follicles in groups of 1 to 4 hairs, transplantation takes advantage of these naturally occurring follicular units. This achieves a more natural appearance by matching hair for hair through Follicular Unit Transplantation (FUT).
Donor hair can be harvested in two different ways. Small grafts of naturally-occurring units of one to four hairs, called follicular units, can be moved to balding areas of the hair restoration. These follicular units are surgically implanted in the scalp in very close proximity to one another and in large numbers. The grafts are obtained in one or both of the two primary methods of surgical extraction, Follicular Unit Transplantation (FUT), colloquially referred to as 'strip harvesting,' or Follicular Unit Extraction (FUE), in which follicles are transplanted individually.
In FUT, a strip of skin containing many follicular units is extracted from the patient and dissected under stereoscopic microscope. Once divided into follicular unit grafts, the surgeon implants each individually into small recipient sites made by incision at the bald scalp. In newer technique, roots are extracted from the donor area and divided into strips for transplantation. The strip, two to three millimeters thick, is isolated and transplanted to bald scalp. After surgery, bandaging is worn for two days for healing.
More recently, bioengineered hair follicles have been successfully transplanted to create histologically normal hair follicles. Specifically, bioengineered hair follicle germ, which was reconstituted with embryonic skin-derived epithelial and mesenchymal cells were ectopically transplanted. On histology, the bioengineered hair follicles also autonomously connected with nerves and the arrector pili muscle at the permanent region and exhibited piloerection ability.
The field of research to prevent and treat androgenic hair loss is vast, with systemic and topical therapies with varying degrees of efficacy. In the United States alone, it is a multi-billion dollar industry. The entire field of research cannot be appropriately addressed in a single article, but the following section discusses those with the greatest degree of peer reviewed research and recognition.
Prostaglandin F2α (PGF2a) analogues induces hair regrowth in animal models of androgenic alopecia with transgenic mice, and stump-tailed macaques, and initially generated 'great expectations' in pharmaceutical research for potential effectiveness in alopecia. Latanoprost and bimatoprost are specific PGF2a analogues applied topically, and have been found to lengthen eyelashes, darken hair pigmentation and elongate hair. Bimatoprost (Latisse®) is available as treatment for eyelash growth. Latanoprost (Xalatan®) has shown ability to promote scalp hair density and pigmentation, and is theorized to function at the dermal papilla. A study found latanoprost ineffective on eyelashes in a patient with alopecia areata. It has also been found ineffective in treatment of eyebrow hair loss. A study in which a combination of subcutaneous capsaicin and isoflavone was administered to bald (CGRP knockout) mice resulted in rise of dermal IGF-1 at hair follicles and hair regrowth. The mechanism was thought to be through activation of vanilloid receptor-1 causing release of CGRP from neurons, in turn causing release of IGF-1. Other studies on less painful medications found topical raspberry extract to work through a similar mechanism. Caffeine stimulates human hair growth in vitro, and reduced testosterone-induced follicle growth suppression. It has been demonstrated that the addition of caffeine to a shampoo-formulation is effective in administering caffeine to the hair follicles in the scalp. Further research must be done to evaluate the efficacy and adequate dosage of caffeine in the treatment of androgenetic alopecia. Cyproterone acetate is a topical agent in a lipid suspension that has anti-androgenic activity at the pilosebaceous unit. It has shown similar efficacy to 2% minoxidil in treatment of female androgenic hair loss, with cyproterone acetate being more effective when women had high body mass indices, and minoxidil more effective when they weighed less. It has also been shown effective in acne and hirsutism, but no longer marketed due to theoretical risks of venous thromboembolism. More recent studies have shown that this risk is no greater than that seen with oral contraceptives. Estrogens are indirect anti-androgens, and can be used to treat androgenetic hair loss in females with oral contraceptives. Systemic estrogen increases SHBG, which binds androgens, including testosterone and DHT, in turn reducing their bioavailability. Topical formulations are available in Europe. Hair follicles have estrogen receptors and it is theorized topical compounds act on them directly to promote hair growth and antagonize androgen action. Large clinical studies showing effectiveness are absent. Topical treatment is also usually unavailable in North America. HIF-1 help prevents apoptosis, or cell death, in hypoxic conditions. In vitro, when supernatant from HIF-1 transfected fibroblast cells was administered to hair follicle cells, it induced VEGF, which had stimulatory effects on hair follicle cells. VEGF promotes growth of blood vessels, which would be an appropriate response to low oxygen conditions. Other studies have suggested hypoxia initiates a potentially self-perpetuating cycle involving HIF, VEGF, and AKT activation. Ciclopirox, otherwise known as ciclopiroxolamine, is used as a topical shampoo, has anti-fungal properties, and may induce HIF-1.
In December 2012, topical application of IGF-1 in a liposomal vehicle led to thicker and more rapid hair growth in transgenic mice with androgenic alopecia. The study did not show measurable systemic levels or hematopoietic side effects, suggesting potential for use in humans. Low energy radiofrequency irradiation induces IGF-1 in cultured human dermal papilla cells. Adenosine stimulates dermal papillae in vitro to induce IGF-1, along with fibroblast growth factors FGF7, FGF-2 and VEGF. β-catenin transcription increased, which promotes dermal papillae as well. Dietary isoflavones increase IGF production in scalp dermal papillae in transgenic mice. Topical capsaicin also stimulates IGF at hair follicles via release of vanilloid receptor-1, which in turn leads to more CGRP. Ascorbic acid has led to increased IGF expression in vitro.
Piroctone olamine is a topical agent that has similar efficacy to 1% ketoconazole in small controlled trials. In 2012, scientists found the lipid prostaglandin D2 (PGD2) in balding male scalps at levels higher than controls, and theorized it prevented hair follicles maturation. The lead investigator said treatment could be possible within two years. Ginger can affect PGD2 levels in serum. Mouse models have found valproic acid activates alkaline phosphatase in human dermal papilla cells and induces hair regeneration in transgenic mice. Systemic valproic acid can cause alopecia, although this may be related to deficiencies of biotin and zinc.
In May 2007, U.S. company Follica Inc licensed technology from the University of Pennsylvania to regenerate hair follicles by reawakening genes from embryonic development. Studies began with the study of hair regrowth in wound healing in mice when Wnt proteins were introduced. Time to development of pharmaceutical treatment is expected to take several years. In other methods, cells are cultured and the supernatant is processed to produce a compound rich in hair growth promoting factors, like Wnt proteins. This approach is still in Phase I or II trials. Platelet rich plasma (PRP) isolated from whole blood can be used for its growth factors and stimulatory mediators. Some hair transplant surgeons use this product to encourage transplanted graft growth. PRP is also available as a standalone treatment for AGA, though there is only one small study to date in its support.
The dietary supplement industry is distinct from the pharmaceutical industry, and is more loosely regulated than FDA approved medications. The most commonly used and well researched plants are saw palmetto (Serenoa repens), stinging nettle (Urtica dioica), turmeric (Curcubita pepo), and Pygeum africanum. Other herbs include black cohosh (Actaea racemosa), dong quai (Angelica sinensis), false unicorn (Chamaelirium luteum), chasteberry (Vitex agnus-castus), and red clover (Trifolium pratense). Each of them purport hair promoting effects by various mechanisms. Common nutritional supplements include biotin, caffeine and melatonin. Other supplements for hair loss include L-arginine,, Boswellia serrata,, biotin, L-Carnitine, TRX2 is a dietary supplement that predominantly contains carnitine., curcumin, ginger, grape seed extract, Grateloupia elliptica, green tea, lycopene, pumpkin seed oil (Curcurbitae pepo), and resveratrol.
Saw palmetto (Sabal serrulatum or Serenao repens) may inhibit 5 alpha reductase and is approved for treatment of prostate disorders in Germany as well. Studies of Italian men have found it effective at 320 mg/day. Saw palmetto in one small study demonstrated increased hair growth in 6/10 men with mild to moderate androgenetic alopecia, and another study revealed that saw palmetto extract applied topically in a lotion and shampoo base led to a 35% increase in hair density, but these studies were incredibly small and a proper larger clinical trial on androgenetic alopecia is needed. A meta-analysis looking at effects of Serenao in BPH and prostate adenocarcinoma was unable to make conclusions regarding its effects in BPH due to limitations of studies in the literature.
Nettle (Urtica dioica) inhibits 5 alpha reductase in vitro when given in combination with Pygeum africanum. It ameliorates symptoms of BPH in rats, and has been found protective against reperfusion injury in organ ischemia. Nettle is approved for treatment of prostate disorders in Germany.
Pygeum africanum inhibits 5 alpha reductase in vitro when given with Nettle (Urtica dioica). In vitro cultured prostate stromal cells from patients with BPH show the herb to induce apoptosis. N-butylbenzene-sulfonamide (NBBS), isolated from Pygeum africanum bark, acts as an androgen antagonistic, inhibits AR nuclear translocation and prostate cancer cell growth. Atraric acid, isolated from bark material of Pygeum africanum, has anti-androgenic activity, inhibiting transactivation mediated by ligand-activated human AR. A meta-analysis looking at effects of Pygeum africanum in BPH and prostate adenocarcinoma was unable to make conclusions regarding its effects in BPH due to limitations of studies in the literature.
Stem cell therapy
Although follicles were previously thought gone in areas of complete baldness, they are more likely dormant, as recent studies have shown the scalp contains the stem cells from which the follicles arose. Research on these follicular stem cells may lead to successes in treating baldness through hair multiplication (HM), also known as hair cloning.
One of the groups developing hair multiplication is Aderans Research Institute (ARI), a Japanese owned company in the United States. In 2008, Intercytex announced results of a Phase II trial to clone hair follicles from the back of the neck, multiply them and then reimplant the cells into the scalp. Initial testing showed at least two thirds of male patients regrew hair. The company estimated treatment would take "a number of years to complete" Phase III trials. After failing to achieve success in their trials, the company discontinued its hair multiplication project in 2010, with intention to sell off its assets and research. Aderans Research Institute Inc. (ARI) then acquired technology from Regenerative Medicine Assets Limited (formerly Intercytex Group plc) and is conducting Phase II clinical trials.
Scientists grew the first artificial hair follicles from stem cells in 2010. Researchers in the study predicted that by 2015 people could grow new hair from their own stem cells, and have it surgically implanted at areas of hair loss. The lead investigator said preparations for clinical trials were "already in motion". In their first human clinical trial, Replicel Life Sciences was able to regenerate 20% percent of hair on stem cell treated areas. Replicel is using dermal sheath cup cells instead of dermal papillae cells for multiplication, in distinction to Aderans. They will be conducting Phase II trials at the end of 2012. In early 2012 a research group demonstrated "functional hair regeneration from adult stem cells" in mouse animal models with the potential for "organ replacement regenerative therapies".
Curis and Procter & Gamble spent $1,000,000 on development of a topical hedgehog agonist for hair loss. The agent did not meet safety standards, and the program was stopped in 2007. In 2008 researchers at the University of Bonn announced they have found the genetic basis of two distinct forms of inherited hair loss. They found the gene P2RY5 causes a rare, inherited form of hair loss called hypotrichosis simplex. It is the first receptor in humans known to play a role in hair growth. Researchers found that disruption of the gene SOX21 in mice caused cyclical hair loss. Research has suggested SOX21 as a master regulator of hair shaft cuticle differentiation, with its disruption causing cyclical alopecia in mice models. Deletion of SOX21 dramatically affects hair lipids.
Radiation induced alopecia
Radiation induces alopecia through damage to hair follicle stem cell progenitors and alteration of keratin expression. Radiation therapy has been associated with increased mucin production in hair follicles.
Studies have suggested electromagnetic radiation as a therapeutic growth stimulant in alopecia.
Certain hair shampoos and ointments visually thicken existing hair, without affecting the growth cycle. There have also been developments in the fashion industry with wig design. The fashion accessory has also been shown to be a source of psychological support for women undergoing chemotherapy, with cancer survivors in one study describing their wig as a "constant companion". Other studies in women have demonstrated a more mixed psychosocial impact of hairpiece use.
Recently, prototypes of 'follicular unit wigs' have been trialed in rabbit models, with good histocompatibility, a low loss rate, and satisfactory appearance in a year after transplantation.
- Androgenic alopecia
- Hamilton-Norwood scale
- Ludwig scale
- Noncicatricial alopecia
- Hordinsky, M. K. (2006). "Medical Treatment of Noncicatricial Alopecia". Seminars in Cutaneous Medicine and Surgery 25 (1): 51–55. doi:10.1016/j.sder.2006.01.007. PMID 16616303.
- "The Bald Truth About Hair Loss In Young Men". Stephanie Whyche, InteliHealth News Service. August 8, 2002. Retrieved December 16, 2012.
- "Help for Hair Loss: Men's Hair Loss – Causes". Webmd.com. March 1, 2010.
- Inui, S.; Itami, S. (2012). "Androgen actions on the human hair follicle: Perspectives". Experimental Dermatology: n/a. doi:10.1111/exd.12024. PMID 23016593.
- Soni, V. K. (2009). "Androgenic alopecia: A counterproductive outcome of the anabolic effect of androgens". Medical Hypotheses 73 (3): 420–426. doi:10.1016/j.mehy.2009.03.032. PMID 19477078.
- "Female pattern baldness". MedlinePlus. December 15, 2012. Retrieved December 15, 2012.
- Caroli, S.; Pathomvanich, D.; Amonpattana, K.; Kumar, A. (2011). "Current status of hair restoration surgery". International surgery 96 (4): 345–351. PMID 22808618.
- Rose, P. (2011). "The Latest Innovations in Hair Transplantation". Facial Plastic Surgery 27 (4): 366–377. doi:10.1055/s-0031-1283055. PMID 21792780.
- Elisabeth Leamy (May 31, 2012). "Considering a hair tattoo? Pro's and cons to consider before you commit". ABC News. Retrieved December 16, 2012.
- Bella Battle (February 11, 2012). "Wish you were hair". The Sun (London). Retrieved December 16, 2012.
- Kovalevsky, G.; Ballagh, S. A.; Stanczyk, F. Z.; Lee, J.; Cooper, J.; Archer, D. F. (2010). "Levonorgestrel effects on serum androgens, sex hormone–binding globulin levels, hair shaft diameter, and sexual function". Fertility and Sterility 93 (6): 1997–2003. doi:10.1016/j.fertnstert.2008.12.095. PMID 19394598.
- Giorgi, A.; Weatherby, R. P.; Murphy, P. W. (1999). "Muscular strength, body composition and health responses to the use of testosterone enanthate: A double blind study". Journal of science and medicine in sport / Sports Medicine Australia 2 (4): 341–355. doi:10.1016/S1440-2440(99)80007-3. PMID 10710012.
- Tremblay, M. S.; Copeland, J. L.; Van Helder, W. (2004). "Effect of training status and exercise mode on endogenous steroid hormones in men". Journal of Applied Physiology 96 (2): 531–539. doi:10.1152/japplphysiol.00656.2003. PMID 14514704.
- Arce, J. C.; De Souza, M. J.; Pescatello, L. S.; Luciano, A. A. (1993). "Subclinical alterations in hormone and semen profile in athletes". Fertility and sterility 59 (2): 398–404. PMID 8425638.
- Hackney, A. C.; Sinning, W. E.; Bruot, B. C. (1988). "Reproductive hormonal profiles of endurance-trained and untrained males". Medicine and science in sports and exercise 20 (1): 60–65. PMID 3343919.
- Wheeler, G. D.; Wall, S. R.; Belcastro, A. N.; Cumming, D. C. (1984). "Reduced serum testosterone and prolactin levels in male distance runners". JAMA : the journal of the American Medical Association 252 (4): 514–516. PMID 6429357.
- Cooper, C. S.; Taaffe, D. R.; Guido, D.; Packer, E.; Holloway, L.; Marcus, R. (1998). "Relationship of chronic endurance exercise to the somatotropic and sex hormone status of older men". European journal of endocrinology / European Federation of Endocrine Societies 138 (5): 517–523. PMID 9625362.
- Häkkinen, K.; Pakarinen, A.; Alen, M.; Kauhanen, H.; Komi, P. V. (1988). "Neuromuscular and hormonal adaptations in athletes to strength training in two years". Journal of applied physiology (Bethesda, Md. : 1985) 65 (6): 2406–2412. PMID 3215840.
- Kraemer, W. J.; Häkkinen, K.; Newton, R. U.; McCormick, M.; Nindl, B. C.; Volek, J. S.; Gotshalk, L. A.; Fleck, S. J.; Campbell, W. W.; Gordon, S. E.; Farrell, P. A.; Evans, W. J. (1998). "Acute hormonal responses to heavy resistance exercise in younger and older men". European journal of applied physiology and occupational physiology 77 (3): 206–211. doi:10.1007/s004210050323. PMID 9535580.
- Tremblay, M. S.; Copeland, J. L.; Van Helder, W. (2004). "Effect of training status and exercise mode on endogenous steroid hormones in men". Journal of Applied Physiology 96 (2): 531–539. doi:10.1152/japplphysiol.00656.2003. PMID 14514704.
- Hackney, A. C.; Premo, M. C.; McMurray, R. G. (1995). "Influence of aerobic versus anaerobic exercise on the relationship between reproductive hormones in men". Journal of Sports Sciences 13 (4): 305–311. doi:10.1080/02640419508732244. PMID 7474044.
- Fellmann, N.; Coudert, J.; Jarrige, J. -F.; Bedu, M.; Denis, C.; Boucher, D.; Lacour, J. -R. (2008). "Effects of Endurance Training on the Androgenic Response to Exercise in Man". International Journal of Sports Medicine 06 (4): 215–219. doi:10.1055/s-2008-1025843. PMID 4044106.
- Hackney, A. C.; Fahrner, C. L.; Gulledge, T. P. (1998). "Basal reproductive hormonal profiles are altered in endurance trained men". The Journal of sports medicine and physical fitness 38 (2): 138–141. PMID 9763799.
- Jensen, J.; Oftebro, H.; Breigan, B.; Johnsson, A.; Ohlin, K.; Meen, H. D.; Strømme, S. B.; Dahl, H. A. (1991). "Comparison of changes in testosterone concentrations after strength and endurance exercise in well trained men". European journal of applied physiology and occupational physiology 63 (6): 467–471. PMID 1765061.
- Hawkins, V. N.; Foster-Schubert, K.; Chubak, J.; Sorensen, B.; Ulrich, C. M.; Stancyzk, F. Z.; Plymate, S.; Stanford, J.; White, E.; Potter, J. D.; McTiernan, A. (2008). "Effect of Exercise on Serum Sex Hormones in Men". Medicine & Science in Sports & Exercise 40 (2): 223–233. doi:10.1249/mss.0b013e31815bbba9. PMC 3040039. PMID 18202581.
- Bunt, J. C. (1986). "Hormonal alterations due to exercise". Sports medicine (Auckland, N.Z.) 3 (5): 331–345. PMID 3529282.
- Alén, M.; Pakarinen, A.; Häkkinen, K.; Komi, P. V. (1988). "Responses of serum androgenic-anabolic and catabolic hormones to prolonged strength training". International journal of sports medicine 9 (3): 229–233. PMID 3410630.
- Häkkinen, K.; Pakarinen, A.; Alén, M.; Kauhanen, H.; Komi, P. V. (1987). "Relationships between training volume, physical performance capacity, and serum hormone concentrations during prolonged training in elite weight lifters". International journal of sports medicine. 8 Suppl 1: 61–65. PMID 3108174.
- Häkkinen, K.; Pakarinen, A. (2007). "Acute Hormonal Responses to Heavy Resistance Exercise in Men and Women at Different Ages". International Journal of Sports Medicine 16 (8): 507–513. doi:10.1055/s-2007-973045. PMID 8776203.
- Häkkinen, K.; Pakarinen, A.; Newton, R. U.; Kraemer, W. J. (1998). "Acute hormone responses to heavy resistance lower and upper extremity exercise in young versus old men". European journal of applied physiology and occupational physiology 77 (4): 312–319. PMID 9562359.
- Ara, I.; Perez-Gomez, J.; Vicente-Rodriguez, G.; Chavarren, J.; Dorado, C.; Calbet, J. A. (2006). "Serum free testosterone, leptin and soluble leptin receptor changes in a 6-week strength-training programme". The British journal of nutrition 96 (6): 1053–1059. PMID 17181880.
- Nicklas, B.; Ryan, A.; Treuth, M.; Harman, S.; Blackman, M.; Hurley, B.; Rogers, M. (2007). "Testosterone, Growth Hormone and IGF-I Responses to Acute and Chronic Resistive Exercise in Men Aged 55-70 Years". International Journal of Sports Medicine 16 (7): 445–450. doi:10.1055/s-2007-973035. PMID 8550252.
- Ahtiainen, J. P.; Pakarinen, A.; Alen, M.; Kraemer, W. J.; h�Kkinen, K. (2003). "Muscle hypertrophy, hormonal adaptations and strength development during strength training in strength-trained and untrained men". European Journal of Applied Physiology 89 (6): 555–563. doi:10.1007/s00421-003-0833-3. PMID 12734759.
- Goto, K.; Higashiyama, M.; Ishii, N.; Takamatsu, K. (2005). "Prior endurance exercise attenuates growth hormone response to subsequent resistance exercise". European Journal of Applied Physiology 94 (3): 333–338. doi:10.1007/s00421-004-1296-x. PMID 15714290.
- Gorostiaga, E. M.; Izquierdo, M.; Ruesta, M.; Iribarren, J.; González-Badillo, J. J.; Ibáñez, J. (2003). "Strength training effects on physical performance and serum hormones in young soccer players". European Journal of Applied Physiology 91 (5–6): 698–707. doi:10.1007/s00421-003-1032-y. PMID 14704801.
- "Propecia & Rogaine for Treating Male Pattern Baldness". Webmd.com. Retrieved May 19, 2010.
- "FDA's Role". Fda.gov. June 23, 2009. Retrieved May 19, 2010.
- McElwee, K. J.; Shapiro, J. S. (2012). "Promising therapies for treating and/or preventing androgenic alopecia". Skin therapy letter 17 (6): 1–4. PMID 22735503.
- Khandpur, S.; Suman, M.; Reddy, B. S. (2002). "Comparative efficacy of various treatment regimens for androgenetic alopecia in men". The Journal of dermatology 29 (8): 489–498. PMID 12227482.
- Hajheydari, Z.; Akbari, J.; Saeedi, M.; Shokoohi, L. (2009). "Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia". Indian journal of dermatology, venereology and leprology 75 (1): 47–51. PMID 19172031.
- Andersson, S. (2001). "Steroidogenic enzymes in skin". European journal of dermatology : EJD 11 (4): 293–295. PMID 11399532.
- Leyden, J.; Dunlap, F.; Miller, B.; Winters, P.; Lebwohl, M.; Hecker, D.; Kraus, S.; Baldwin, H.; Shalita, A.; Draelos, Z.; Markou, M.; Thiboutot, D.; Rapaport, M.; Kang, S.; Kelly, T.; Pariser, D.; Webster, G.; Hordinsky, M.; Rietschel, R.; Katz, H. I.; Terranella, L.; Best, S.; Round, E.; Waldstreicher, J. (1999). "Finasteride in the treatment of men with frontal male pattern hair loss". Journal of the American Academy of Dermatology 40 (6 Pt 1): 930–937. doi:10.1016/S0190-9622(99)70081-2. PMID 10365924.
- Barth, J. H. (2000). "Should men still go bald gracefully?". The Lancet 355 (9199): 161–162. doi:10.1016/S0140-6736(99)00412-2. PMID 10675111.
- Proof of results with PROPECIA
- Azeem, A.; Khan, Z. I.; Aqil, M.; Ahmad, F. J.; Khar, R. K.; Talegaonkar, S. (2009). "Microemulsions as a Surrogate Carrier for Dermal Drug Delivery". Drug Development and Industrial Pharmacy 35 (5): 525–547. doi:10.1080/03639040802448646. PMID 19016057.
- Kumar, R.; Singh, B.; Bakshi, G.; Katare, O. P. (2007). "Development of Liposomal Systems of Finasteride for Topical Applications: Design, Characterization, and in Vitro Evaluation". Pharmaceutical Development and Technology 12 (6): 591–601. doi:10.1080/10837450701481181. PMID 18161632.
- Ye, F.; Imamura, K.; Imanishi, N.; Rhodes, L.; Uno, H. (1997). "Effects of topical antiandrogen and 5-alpha-reductase inhibitors on sebaceous glands in male fuzzy rats". Skin pharmacology : the official journal of the Skin Pharmacology Society 10 (5–6): 288–297. PMID 9449168.
- Póltorak, J. L. (1976). "Bile duct calculosis". Polski tygodnik lekarski (Warsaw, Poland : 1960) 31 (4): 145–148. PMID 1250761.
- Sintov, A.; Serafimovich, S.; Gilhar, A. (2000). "New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice". International journal of pharmaceutics 194 (1): 125–134. PMID 10601691.
- Madheswaran, T.; Baskaran, R.; Thapa, R. K.; Rhyu, J. Y.; Choi, H. Y.; Kim, J. O.; Yong, C. S.; Yoo, B. K. (2012). "Design and in Vitro Evaluation of Finasteride-Loaded Liquid Crystalline Nanoparticles for Topical Delivery". AAPS PharmSciTech. doi:10.1208/s12249-012-9888-y. PMID 23207960.
- Tanglertsampan, C. (2012). "Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: A randomized, double-blind, comparative study". Journal of the Medical Association of Thailand = Chotmaihet thangphaet 95 (10): 1312–1316. PMID 23193746.
- Rafi, A. W.; Katz, R. M. (2011). "Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA". ISRN Dermatology 2011: 1. doi:10.5402/2011/241953. PMC 3262531. PMID 22363845.
- Javadzadeh, Y.; Shokri, J.; Hallaj-Nezhadi, S.; Hamishehkar, H.; Nokhodchi, A. (2010). "Enhancement of percutaneous absorption of Finasteride by cosolvents, cosurfactant and surfactants". Pharmaceutical Development and Technology 15 (6): 619–625. doi:10.3109/10837450903397610. PMID 19929166.
- Hajheydari, Z.; Akbari, J.; Saeedi, M.; Shokoohi, L. (2009). "Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia". Indian journal of dermatology, venereology and leprology 75 (1): 47–51. PMID 19172031.
- Price, T. M.; Allen, S.; Pegram, G. V. (2000). "Lack of effect of topical finasteride suggests an endocrine role for dihydrotestosterone". Fertility and sterility 74 (2): 414–415. PMID 10927075.
- Irwig, M. S. (2012). "Depressive Symptoms and Suicidal Thoughts Among Former Users of Finasteride with Persistent Sexual Side Effects". The Journal of Clinical Psychiatry 73 (9): 1220–1223. doi:10.4088/JCP.12m07887. PMID 22939118.
- Avodart 0.5 mg soft capsules | SPC from the eMC
- Olsen EA, Hordinsky M, Whiting D, et al. (December 2006). "The importance of dual 5alpha-reductase inhibition in the treatment of MPB: results of a randomized placebo-controlled study of dutasteride versus finasteride". J Am Acad Dermatol. 55 (6): 1014–23. doi:10.1016/j.jaad.2006.05.007. PMID 17110217.
- ClinicalTrials.gov NCT00441116
- Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study | Journal of the American Academy of Dermatology (JAAD)
- https://en.wikipedia.org/wiki/Ketoconazole#Hair_loss Ketoconazole Article in Wikipedia
- http://www.regenepure.com/ Regenepure Shampoo website
- Beyond the Vertex – Objective evidence shows minoxidil's frontal-scalp performance | ModernMedicine
- Jasek, W, ed. (2007). Austria-Codex (in German) 4 (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. p. 9673. ISBN 978-3-85200-181-4.
- Olsen, E. A.; Whiting, D.; Bergfeld, W.; Miller, J.; Hordinsky, M.; Wanser, R.; Zhang, P.; Kohut, B. (2007). "A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men". Journal of the American Academy of Dermatology 57 (5): 767–774. doi:10.1016/j.jaad.2007.04.012. PMID 17761356.
- Hair loss, cure review (2013). "Hair loss cure review" (in English). Hair loss cure.
- Rathnayake, D.; Sinclair, R. (2010). "Innovative Use of Spironolactone as an Antiandrogen in the Treatment of Female Pattern Hair Loss". Dermatologic Clinics 28 (3): 611–618. doi:10.1016/j.det.2010.03.011. PMID 20510769.
- Rathnayake, D.; Sinclair, R. (2010). "Use of spironolactone in dermatology". Skinmed 8 (6): 328–332; quiz 332. PMID 21413648.
- Piérard-Franchimont, C.; De Doncker, P.; Cauwenbergh, G.; PiÉRard, G. E. (1998). "Ketoconazole shampoo: Effect of long-term use in androgenic alopecia". Dermatology (Basel, Switzerland) 196 (4): 474–477. doi:10.1159/000017954. PMID 9669136.
- Magro, C. M.; Rossi, A.; Poe, J.; Manhas-Bhutani, S.; Sadick, N. (2011). "The role of inflammation and immunity in the pathogenesis of androgenetic alopecia". Journal of drugs in dermatology : JDD 10 (12): 1404–1411. PMID 22134564.
- Inui, S.; Itami, S. (2007). "Reversal of androgenetic alopecia by topical ketoconzole: Relevance of anti-androgenic activity". Journal of Dermatological Science 45 (1): 66–68. doi:10.1016/j.jdermsci.2006.08.011. PMID 16997533.
- Sundar, S.; Dickinson, P. D. (2012). "Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate". Case Reports 2012: bcr1120115238. doi:10.1136/bcr.11.2011.5238. PMID 22665559.
- Adenuga, P.; Summers, P.; Bergfeld, W. (2012). "Hair regrowth in a male patient with extensive androgenetic alopecia on estrogen therapy". Journal of the American Academy of Dermatology 67 (3): e121–e123. doi:10.1016/j.jaad.2011.10.017. PMID 22890743.
- Buchanan, J. F.; Davis, L. J. (1984). "Drug-induced infertility". Drug intelligence & clinical pharmacy 18 (2): 122–132. PMID 6141923.
- Sinclair, R.; Patel, M.; Dawson, T. L.; Yazdabadi, A.; Yip, L.; Perez, A.; Rufaut, N. W. (2011). "Hair loss in women: Medical and cosmetic approaches to increase scalp hair fullness". British Journal of Dermatology 165: 12–18. doi:10.1111/j.1365-2133.2011.10630.x. PMID 22171680.
- Artini, P. G.; Di Berardino, O. M.; Simi, G.; Papini, F.; Ruggiero, M.; Monteleone, P.; Cela, V. (2010). "Best methods for identification and treatment of PCOS". Minerva ginecologica 62 (1): 33–48. PMID 20186113.
- Paradisi, R.; Porcu, E.; Fabbri, R.; Seracchioli, R.; Battaglia, C.; Venturoli, S. (2011). "Prospective Cohort Study on the Effects and Tolerability of Flutamide in Patients with Female Pattern Hair Loss". Annals of Pharmacotherapy 45 (4): 469–475. doi:10.1345/aph.1P600. PMID 21487083.
- Yazdabadi, A.; Sinclair, R. (2011). "Treatment of female pattern hair loss with the androgen receptor antagonist flutamide". Australasian Journal of Dermatology 52 (2): 132–134. doi:10.1111/j.1440-0960.2010.00735.x. PMID 21605098.
- Rashid, R. M.; Morgan Bicknell, L. T. (2012). "Follicular unit extraction hair transplant automation: Options in overcoming challenges of the latest technology in hair restoration with the goal of avoiding the line scar". Dermatology online journal 18 (9): 12. PMID 23031379.
- Caroli, S.; Pathomvanich, D.; Amonpattana, K.; Kumar, A. (2011). "Current status of hair restoration surgery". International surgery 96 (4): 345–351. PMID 22808618.
- Asakawa, K.; Toyoshima, K. E.; Ishibashi, N.; Tobe, H.; Iwadate, A.; Kanayama, T.; Hasegawa, T.; Nakao, K.; Toki, H.; Noguchi, S.; Ogawa, M.; Sato, A.; Tsuji, T. (2012). "Hair organ regeneration via the bioengineered hair follicular unit transplantation". Scientific Reports 2: 424. doi:10.1038/srep00424. PMC 3361021. PMID 22645640.
- Sasaki, S.; Hozumi, Y.; Kondo, S. (2005). "Influence of prostaglandin F2alpha and its analogues on hair regrowth and follicular melanogenesis in a murine model". Experimental Dermatology 14 (5): 323–328. doi:10.1111/j.0906-6705.2005.00270.x. PMID 15854125.
- Uno, H.; Zimbric, M. L.; Albert, D. M.; Stjernschantz, J. (2002). "Effect of latanoprost on hair growth in the bald scalp of the stump-tailed macacque: A pilot study". Acta dermato-venereologica 82 (1): 7–12. PMID 12013211.
- Wolf, R.; Matz, H.; Zalish, M.; Pollack, A.; Orion, E. (2003). "Prostaglandin analogs for hair growth: Great expectations". Dermatology online journal 9 (3): 7. PMID 12952754.
- Law, S. K. (2010). "Bimatoprost in the treatment of eyelash hypotrichosis". Clinical ophthalmology (Auckland, N.Z.) 4: 349–358. PMC 2861943. PMID 20463804.
- Tosti, A.; Pazzaglia, M.; Voudouris, S.; Tosti, G. (2004). "Hypertrichosis of the eyelashes caused by bimatoprost". Journal of the American Academy of Dermatology 51 (5): S149–S150. doi:10.1016/j.jaad.2004.05.002. PMID 15577756.
- Wand, M. (1997). "Latanoprost and hyperpigmentation of eyelashes". Archives of ophthalmology 115 (9): 1206–1208. PMID 9298071.
- Banaszek, A. (2011). "Company profits from side effects of glaucoma treatment". Canadian Medical Association Journal 183 (14): E1058–E10F1. doi:10.1503/cmaj.109-3919. PMC 3185096. PMID 21876012.
- Blume-Peytavi, U.; Lönnfors, S.; Hillmann, K.; Garcia Bartels, N. (2012). "A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia". Journal of the American Academy of Dermatology 66 (5): 794–800. doi:10.1016/j.jaad.2011.05.026. PMID 21875758.
- Johnstone, M. A.; Albert, D. M. (2002). "Prostaglandin-induced hair growth". Survey of ophthalmology. 47 Suppl 1: S185–S202. PMID 12204716.
- Roseborough, I.; Lee, H.; Chwalek, J.; Stamper, R. L.; Price, V. H. (2009). "Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata". Journal of the American Academy of Dermatology 60 (4): 705–706. doi:10.1016/j.jaad.2008.08.029. PMID 19293023.
- Ross, E. K.; Bolduc, C.; Lui, H.; Shapiro, J. (2005). "Lack of efficacy of topical latanoprost in the treatment of eyebrow alopecia areata". Journal of the American Academy of Dermatology 53 (6): 1095–1096. doi:10.1016/j.jaad.2005.06.031. PMID 16310083.
- Harada, N.; Okajima, K.; Arai, M.; Kurihara, H.; Nakagata, N. (2007). "Administration of capsaicin and isoflavone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia". Growth Hormone & IGF Research 17 (5): 408–415. doi:10.1016/j.ghir.2007.04.009. PMID 17569567.
- Harada, N.; Okajima, K.; Narimatsu, N.; Kurihara, H.; Nakagata, N. (2008). "Effect of topical application of raspberry ketone on dermal production of insulin-like growth factor-I in mice and on hair growth and skin elasticity in humans". Growth Hormone & IGF Research 18 (4): 335–344. doi:10.1016/j.ghir.2008.01.005. PMID 18321745.
- Fischer TW, Hipler UC, Elsner P (January 2007). "Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro". International Journal of Dermatology 46 (1): 27–35. doi:10.1111/j.1365-4632.2007.03119.x. PMID 17214716.
- Otberg N, Teichmann A, Rasuljev U, Sinkgraven R, Sterry W, Lademann J (2007). "Follicular penetration of topically applied caffeine via a shampoo formulation". Skin Pharmacology and Physiology 20 (4): 195–8. doi:10.1159/000101389. PMID 17396054.
- Štecová, J.; Mehnert, W.; Blaschke, T.; Kleuser, B.; Sivaramakrishnan, R.; Zouboulis, C. C.; Seltmann, H.; Korting, H. C.; Kramer, K. D.; Schäfer-Korting, M. (2007). "Cyproterone Acetate Loading to Lipid Nanoparticles for Topical Acne Treatment: Particle Characterisation and Skin Uptake". Pharmaceutical Research 24 (5): 991–1000. doi:10.1007/s11095-006-9225-9. PMID 17372681.
- Vexiau, P.; Chaspoux, C.; Boudou, P.; Fiet, J.; Jouanique, C.; Hardy, N.; Reygagne, P. (2002). "Effects of minoxidil 2% vs. Cyproterone acetate treatment on female androgenetic alopecia: A controlled, 12-month randomized trial". The British journal of dermatology 146 (6): 992–999. doi:10.1046/j.1365-2133.2002.04798.x. PMID 12072067.
- Franks, S.; Layton, A.; Glasier, A. (2007). "Cyproterone acetate/ethinyl estradiol for acne and hirsutism: Time to revise prescribing policy". Human Reproduction 23 (2): 231–232. doi:10.1093/humrep/dem379. PMID 18083746.
- Blumeyer, A.; Tosti, A.; Messenger, A.; Reygagne, P.; Del Marmol, V.; Spuls, P. I.; Trakatelli, M.; Finner, A.; Kiesewetter, F.; Trüeb, R.; Rzany, B.; Blume-Peytavi, U. (2011). "Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men". JDDG: Journal der Deutschen Dermatologischen Gesellschaft 9: S1–57. doi:10.1111/j.1610-0379.2011.07802.x. PMID 21980982.
- Dai, Y. Q.; Fan, W. X.; Wu, L.; Li, M. Y. (2007). "Effect of hypoxia inducible factor-1alpha on cells of hair follicle". Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 29 (2): 217–221. PMID 17536272.
- Roques, C.; Brousse, S.; Panizzutti, C. D. (2006). "In vitro antifungal efficacy of ciclopirox olamine alone and associated with zinc pyrithione compared to ketoconazole against Malassezia globosa and Malassezia restricta reference strains". Mycopathologia 162 (6): 395–400. doi:10.1007/s11046-006-0075-0. PMID 17146583.
- Castro, R. F.; Azzalis, L. A.; Feder, D.; Perazzo, F. F.; Pereira, E. C.; Junqueira, V. B. C.; Rocha, K. C.; Machado, C. D. A.; Paschoal, F. C.; Gnann, L. A.; Fonseca, F. L. A. (2012). "Safety and efficacy analysis of liposomal insulin-like growth factor-1 in a fluid gel formulation for hair-loss treatment in a hamster model". Clinical and Experimental Dermatology 37 (8): 909–912. doi:10.1111/j.1365-2230.2012.04441.x. PMID 22924775.
- Yoon, S. Y.; Kim, K. T.; Jo, S. J.; Cho, A. R.; Jeon, S. I.; Choi, H. D.; Kim, K. H.; Park, G. S.; Pack, J. K.; Kwon, O. S.; Park, W. Y. (2011). "Induction of Hair Growth by Insulin-Like Growth Factor-1 in 1,763 MHz Radiofrequency-Irradiated Hair Follicle Cells". In Najbauer, Joseph. PLoS ONE 6 (12): e28474. doi:10.1371/journal.pone.0028474. PMC 3229574. PMID 22164296.
- Zhao, J.; Harada, N.; Kurihara, H.; Nakagata, N.; Okajima, K. (2011). "Dietary isoflavone increases insulin-like growth factor-I production, thereby promoting hair growth in mice". The Journal of Nutritional Biochemistry 22 (3): 227–233. doi:10.1016/j.jnutbio.2010.01.008. PMID 20576422.
- Okajima, K.; Harada, N. (2008). "Promotion of insulin-like growth factor-I production by sensory neuron stimulation; molecular mechanism(s) and therapeutic implications". Current medicinal chemistry 15 (29): 3095–3112. PMID 19075656.
- Kwack, M. H.; Shin, S. H.; Kim, S. R.; Im, S. U.; Han, I. S.; Kim, M. K.; Kim, J. C.; Sung, Y. K. (2009). "L-Ascorbic acid 2-phosphate promotes elongation of hair shafts via the secretion of insulin-like growth factor-1 from dermal papilla cells through phosphatidylinositol 3-kinase". British Journal of Dermatology 160 (6): 1157–1162. doi:10.1111/j.1365-2133.2009.09108.x. PMID 19416266.
- "Baldness cure which reverses genetics could start clinical trials in two years". Daily Mail (London).
- Adams, Stephen (August 19, 2012). "Baldness cure could be on shelves in two years". The Daily Telegraph (London).
- Eisenberg, Anne (July 28, 2012). "Baldness Battle, Fought in the Follicle". The New York Times.
- Lee, S. H.; Yoon, J.; Shin, S. H.; Zahoor, M.; Kim, H. J.; Park, P. J.; Park, W. S.; Min Do, D. S.; Kim, H. Y.; Choi, K. Y. (2012). "Valproic Acid Induces Hair Regeneration in Murine Model and Activates Alkaline Phosphatase Activity in Human Dermal Papilla Cells". In Bridger, Joanna Mary. PLoS ONE 7 (4): e34152. doi:10.1371/journal.pone.0034152. PMC 3323655. PMID 22506014.
- Khan, T. A.; Sheng, H.; Mercke, Y. K.; Lippmann, S. B. (1999). "Divalproex-induced alopecia: A case report". Psychiatric services (Washington, D.C.) 50 (11): 1500. PMID 10543866.
- Castro-Gago, M.; Perez-Gay, L.; Gomez-Lado, C.; Castineiras-Ramos, D. E.; Otero-Martinez, S.; Rodriguez-Segade, S. (2011). "The Influence of Valproic Acid and Carbamazepine Treatment on Serum Biotin and Zinc Levels and on Biotinidase Activity". Journal of Child Neurology 26 (12): 1522–1524. doi:10.1177/0883073811409227. PMID 21642615.
- Yilmaz, Y.; Tasdemir, H. A.; Paksu, M. S. (2009). "The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity". European Journal of Paediatric Neurology 13 (5): 439–443. doi:10.1016/j.ejpn.2008.08.007. PMID 18922714.
- First Demonstration of New Hair Follicle Generation in an Animal Model | PENN Medicine News
- Study offers hope of baldness remedy | msnbc.com
- Takikawa, M.; Nakamura, S.; Nakamura, S.; Ishirara, M.; Kishimoto, S.; Sasaki, K.; Yanagibayashi, S.; Azuma, R.; Yamamoto, N.; Kiyosawa, T. (2011). "Enhanced Effect of Platelet-Rich Plasma Containing a New Carrier on Hair Growth". Dermatologic Surgery 37 (12): 1721–1729. doi:10.1111/j.1524-4725.2011.02123.x. PMID 21883644.
- Lee, G. -Y.; Lee, S. -J.; Kim, W. -S. (2011). "The effect of a 1550 nm fractional erbium-glass laser in female pattern hair loss". Journal of the European Academy of Dermatology and Venereology 25 (12): 1450–1454. doi:10.1111/j.1468-3083.2011.04183.x. PMID 21812832.
- Leavitt, M.; Charles, G.; Heyman, E.; Michaels, D. (2009). "HairMax LaserComb® Laser Phototherapy Device in the Treatment of Male Androgenetic Alopecia". Clinical Drug Investigation 29 (5): 283–292. doi:10.2165/00044011-200929050-00001. PMID 19366270.
- Ghanaat, M. (2010). "Types of Hair Loss and Treatment Options, Including the Novel Low-Level Light Therapy and Its Proposed Mechanism". Southern Medical Journal 103 (9): 917–921. doi:10.1097/SMJ.0b013e3181ebcf71. PMID 20689478.
- Azimi, H.; Khakshur, A. A.; Aghdasi, I.; Fallah-Tafti, M.; Abdollahi, M. (2012). "A review of animal and human studies for management of benign prostatic hyperplasia with natural products: Perspective of new pharmacological agents". Inflammation & allergy drug targets 11 (3): 207–221. doi:10.2174/187152812800392715. PMID 22512478.
- Rogers, N. E.; Avram, M. R. (2008). "Medical treatments for male and female pattern hair loss". Journal of the American Academy of Dermatology 59 (4): 547–566; quiz 566–8. doi:10.1016/j.jaad.2008.07.001. PMID 18793935.
- Wolf, B.; Pagon, R. A.; Bird, T. D.; Dolan, C. R.; Stephens, K.; Adam, M. P. (1993). Biotinidase Deficiency. PMID 20301497.
- Tyler, Richard (January 9, 2011). "Thomas Whitfield's German roots help hair loss product launch". The Daily Telegraph (London). Retrieved July 23, 2012.
- Edwards, Jim (January 12, 2011). "Pharma's 4 Best Shots at a Cure for Baldness" (Web). CBSNews.com. CBS News. Retrieved August 1, 2012. "it's actually just another dietary supplement and as such is not approved by the FDA."
- "Minoxidil Alternatives" (Web). MPB Research. Retrieved August 1, 2012.
- Foitzik, K., Hoting, E., Förster, T., Pertile, P. and Paus, R. (November 2007). "L-Carnitine–L-tartrate promotes human hair growth in vitro.". Experimental Dermatology (Web & Printdoi:10.1111/j.1600-0625.2007.00611.x. PMID 17927577.). 16: 936–945. (11): 936–945.
- Kang II, J., Kim, S.-C., Han, S.-C., Hong, H.-J., Jeon, Y.-J., Kim, B., Koh, Y.-S., Yoo, E.-S., Kang, H.-K. Hair-loss preventing effect of Grateloupia elliptica (2012) Biomolecules and Therapeutics, 20(1), pp. 118–120.
- Nguyen, H., Kim, S.M. (2012). Antioxidative, anticholinesterase and antityrosinase activities of the red alga Grateloupia lancifolia extracts. African Journal of Biotechnology, 11(39), pp. 9457–9467 (May 15). Retrieved on 2012-06-14.
- Vahlensieck Jr, W.; Fabricius, P. G.; Hell, U. (1996). "Drug therapy of benign prostatic hyperplasia". Fortschritte der Medizin 114 (31): 407–411. PMID 9036092.
- Mantovani, F. (2010). "Serenoa repens in benign prostatic hypertrophy: Analysis of 2 Italian studies". Minerva urologica e nefrologica = the Italian journal of urology and nephrology 62 (4): 335–340. PMID 20944533.
- Prager N, Bickett K, French N, Marcovici G. (Mar 2002). "A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia.". Journal of alternative and complementary medicine 8 (2): 143–152. doi:10.1089/107555302317371433. PMID 12006122.
- Murugusundram, S. (Jan 2009). "Serenoa Repens: Does It have Any Role in the Management of Androgenetic Alopecia?". Journal of cutaneous and aesthetic surgery 2 (1): 31–32. doi:10.4103/0974-2077.53097. PMC 2840915. PMID 20300369.
- Morán, E.; Budía, A.; Broseta, E.; Boronat, F. (2012). "Fitoterapia en Urología. Evidencia científica actual de su aplicación en hiperplasia benigna de próstata y adenocarcinoma de próstata". Actas Urológicas Españolas. doi:10.1016/j.acuro.2012.07.005. PMID 23058996.
- Hartmann, R. W.; Mark, M.; Soldati, F. (1996). "Inhibition of 5 α-reductase and aromatase by PHL-00801 (Prostatonin®), a combination of PY102 (Pygeum africanum) and UR102 (Urtica dioica) extracts". Phytomedicine 3 (2): 121–128. doi:10.1016/S0944-7113(96)80025-0. PMID 23194959.
- Suzuki, Y.; Ito, Y.; Konno, C.; Furuya, T. (1991). "Effects of tissue cultured ginseng on gastric secretion and pepsin activity". Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 111 (12): 770–774. PMID 1806658.
- Yener, Z.; Celik, I.; Ilhan, F.; Bal, R. (2009). "Effects of Urtica dioica L. Seed on lipid peroxidation, antioxidants and liver pathology in aflatoxin-induced tissue injury in rats". Food and Chemical Toxicology 47 (2): 418–424. doi:10.1016/j.fct.2008.11.031. PMID 19073231.
- Quiles, M. T.; Arbós, M. A.; Fraga, A. N.; De Torres, I. S. M.; Reventós, J.; Morote, J. (2010). "Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)". The Prostate 70 (10): 1044–1053. doi:10.1002/pros.21138. PMID 20503393.
- Papaioannou, M.; Schleich, S.; Roell, D.; Schubert, U.; Tanner, T.; Claessens, F.; Matusch, R.; Baniahmad, A. (2009). "NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth". Investigational New Drugs 28 (6): 729–743. doi:10.1007/s10637-009-9304-y. PMID 19771394.
- Papaioannou, M.; Schleich, S.; Prade, I.; Degen, S.; Roell, D.; Schubert, U.; Tanner, T.; Claessens, F.; Matusch, R.; Baniahmad, A. (2009). "The natural compound atraric acid is an antagonist of the human androgen receptor inhibiting cellular invasiveness and prostate cancer cell growth". Journal of Cellular and Molecular Medicine 13 (8b): 2210–2223. doi:10.1111/j.1582-4934.2008.00426.x. PMID 18627423.
- Garza, L. A.; Yang, C. C.; Zhao, T.; Blatt, H. B.; Lee, M.; He, H.; Stanton, D. C.; Carrasco, L.; Spiegel, J. H.; Tobias, J. W.; Cotsarelis, G. (2011). "Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells". Journal of Clinical Investigation 121 (2): 613–622. doi:10.1172/JCI44478. PMC 3026732. PMID 21206086.
- "Hair Cloning Nears Reality as Baldness Cure". Webmd.com. November 4, 2004. Retrieved August 10, 2006.
- "Big Baldness Breakthrough?". Associated Press. March 15, 2004. Archived from the original on May 25, 2006. Retrieved August 10, 2006.
- "ICX-TRC – Frequently Asked Questions". Intercytex. March 22, 2010. Retrieved May 19, 2010.
- "Intercytex Discontinues its Hair Multiplication Development Operations | Hair Loss Q & A". Regrowhair.com. January 7, 2010. Retrieved May 19, 2010.
- Follicle Neogenesis, Bio Engineered Hair Loss Solution | Aderans Research
- Bates, Claire (December 20, 2010). "Cure for baldness on the horizon as scientists grow world's first hair follicles using stem cells". Daily Mail (London).
- Procter & Gamble (September 19, 2005). "Curis and Procter & Gamble Enter into R&D Agreement for Hair Growth Program". Archived from the original on August 22, 2006. Retrieved August 24, 2006.
- Pasternack, S. M.; Von Kügelgen, I.; Al Aboud, K. A.; Lee, Y. A.; Rüschendorf, F.; Voss, K.; Hillmer, A. M.; Molderings, G. J.; Franz, T.; Ramirez, A.; Nürnberg, P.; Nöthen, M. M.; Betz, R. C. (2008). "G protein–coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth". Nature Genetics 40 (3): 329–334. doi:10.1038/ng.84. PMID 18297070.
- Shimomura, Y.; Wajid, M.; Ishii, Y.; Shapiro, L.; Petukhova, L.; Gordon, D.; Christiano, A. M. (2008). "Disruption of P2RY5, an orphan G protein–coupled receptor, underlies autosomal recessive woolly hair". Nature Genetics 40 (3): 335–339. doi:10.1038/ng.100. PMID 18297072.
- Sprecher, E. (2008). "Disentangling the roots of inherited hair disorders". Nature Genetics 40 (3): 265–266. doi:10.1038/ng0308-265. PMID 18305473.
- Kiso, M.; Tanaka, S.; Saba, R.; Matsuda, S.; Shimizu, A.; Ohyama, M.; Okano, H. J.; Shiroishi, T.; Okano, H.; Saga, Y. (2009). "The disruption of Sox21-mediated hair shaft cuticle differentiation causes cyclic alopecia in mice". Proceedings of the National Academy of Sciences 106 (23): 9292–9297. doi:10.1073/pnas.0808324106. PMC 2695080. PMID 19470461.
- Kawaminami, S.; Breakspear, S.; Saga, Y.; Noecker, B.; Masukawa, Y.; Tsuchiya, M.; Oguri, M.; Inoue, Y.; Ishikawa, K.; Okamoto, M. (2012). "Deletion of theSox21gene drastically affects hair lipids". Experimental Dermatology 21 (12): 974–976. doi:10.1111/exd.12050. PMID 23171466.
- Nanashima, N.; Ito, K.; Ishikawa, T.; Nakano, M.; Nakamura, T. (2012). "Damage of hair follicle stem cells and alteration of keratin expression in external radiation-induced acute alopecia". International Journal of Molecular Medicine 30 (3): 579–584. doi:10.3892/ijmm.2012.1018. PMID 22692500.
- Kamiya, K.; Sasatani, M. (2012). "Effects of radiation exposure on human body". Nihon rinsho. Japanese journal of clinical medicine 70 (3): 367–374. PMID 22514910.
- Takeda, H.; Nakajima, K.; Kaneko, T.; Harada, K.; Matsuzaki, Y.; Sawamura, D. (2011). "Follicular mucinosis associated with radiation therapy". The Journal of Dermatology 38 (11): 1116–1118. doi:10.1111/j.1346-8138.2010.01187.x. PMID 22034994.
- Kalia, S.; Lui, H. (2012). "Utilizing Electromagnetic Radiation for Hair Growth". Dermatologic Clinics 31 (1): 193–200. doi:10.1016/j.det.2012.08.018. PMID 23159188.
- Davis, M. G.; Thomas, J. H.; Van De Velde, S.; Boissy, Y.; Dawson Jr, T. L.; Iveson, R.; Sutton, K. (2011). "A novel cosmetic approach to treat thinning hair". British Journal of Dermatology 165: 24–30. doi:10.1111/j.1365-2133.2011.10633.x. PMID 22171682.
- Zannini, L.; Verderame, F.; Cucchiara, G.; Zinna, B.; Alba, A.; Ferrara, M. (2012). "'My wig has been my journey's companion': Perceived effects of an aesthetic care programme for Italian women suffering from chemotherapy-induced alopecia". European Journal of Cancer Care 21 (5): 650–660. doi:10.1111/j.1365-2354.2012.01337.x. PMID 22339814.
- Inui, S.; Inoue, T.; Itami, S. (2012). "Psychosocial impact of wigs or hairpieces on perceived quality of life level in female patients with alopecia areata". The Journal of Dermatology: n/a. doi:10.1111/1346-8138.12040. PMID 23252418.
- Sun, Y.; Lu, F.; Liu, G.; Zhang, Z. D.; Zhang, Z.; Hu, Z. Q. (2011). "Histocompatibility and Long-Term Results of the Follicular Unit-Like Wigs after Xenogeneic Hair Transplantation: An Experimental Study in Rabbits". ISRN Dermatology 2011: 1. doi:10.5402/2011/134502. PMC 3262550. PMID 22363843.
- The Trichological Society
- How Hair Replacement Works
- International Society of Hair Restoration Surgery
- "Medical Treatments for Balding in Men", April 1999, American Family Physician (medical journal)
- Health Alternatives: zinc, silica, methylsulphonylmethane (MSM) and cod-liver oil, to slow down the process.